1. Home
  2. RAVE vs VERU Comparison

RAVE vs VERU Comparison

Compare RAVE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

HOLD

Current Price

$2.45

Market Cap

35.4M

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.30

Market Cap

36.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
VERU
Founded
1958
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.4M
36.8M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
RAVE
VERU
Price
$2.45
$2.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
23.9K
49.2K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.09
N/A
Revenue
$15,120,000.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.36
52 Week High
$3.75
$4.59

Technical Indicators

Market Signals
Indicator
RAVE
VERU
Relative Strength Index (RSI) 25.47 41.54
Support Level N/A $2.15
Resistance Level $3.49 $2.70
Average True Range (ATR) 0.14 0.12
MACD -0.02 -0.03
Stochastic Oscillator 2.00 22.51

Price Performance

Historical Comparison
RAVE
VERU

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: